12:27 PM
Oct 09, 2018
 |  BC Extra  |  Company News

Management tracks: Pfizer unveils Bourla’s team

Editor's Note: This article was updated on Oct 09, 2018 at 3:44 PM PDT

Incoming Pfizer Inc. (NYSE:PFE) CEO Albert Bourla’s executive team will include a chief digital and technology officer and see Global President of Worldwide R&D and Medical Mikael Dolsten add the title of CMO.

The new head of digital is Lidia Fonseca, who will join Pfizer from Quest Diagnostics Inc. (NYSE:DGX), where she is SVP and chief information officer. Current EVP and CMO Freda Lewis-Hall will become EVP and chief patient officer, which Pfizer spokesperson Joan Campion told BioCentury is a newly created role. Lewis-Hall currently oversees the company's office of patient affairs.

Bourla, who was tapped on Oct. 1 to succeed Ian Read as CEO, will inherit Pfizer under a new business structure that takes effect when he takes over in January and comprises three distinct business units: Innovative Health, Established Medicines and Consumer Healthcare (see “For Pfizer’s Units, Three is the Magic Number”).

Group President of Pfizer Essential Health Angela Hwang will become group president of Pfizer's innovative business. She replaces current Group President of Pfizer Innovative Health John Young, who will become group president and CBO.

In Young’s new role, he will oversee strategy, business development, portfolio management and valuation activities, as well as business analytics, global commercial operations and patient and health impact. Young will also oversee Pfizer’s consumer health business.

Michael Goettler will lead the established medicines business, as previously announced.

Pfizer also announced the retirement at year end of EVP and President of Pfizer Global Supply Kirsten Lund-Jurgensen and EVP of Strategy and Commercial Operations Laurie Olson.

Frank D’Amelio, CFO and EVP of business operations, will now also lead Global Supply, the company’s manufacturing operations. EVP and Chief Development Officer Rod MacKenzie will expand his role to include regulatory affairs.

Continuing in their existing roles are EVP and Chief Compliance Officer Rady Johnson; EVP and General Counsel Doug Lankler; EVP and Chief Corporate Affairs Officer Sally Susman; and EVP and Chief Human Resources Officer Dawn Rogers.

In other management news, vascular company Vasomune Therapeutics Inc. (Toronto, Ontario) hired Douglas Hamilton as president and CEO. He succeeds Parimal Nathwani, who will remain on the board. Hamilton was president and CEO at MetaStat Inc. (The Woodlands, Texas).

Neurology company Bionure Farma S.L. (Menlo Park, Calif.) hired Laurent Nguyen as CEO.

Cerevance Inc. (Boston, Mass.) hired Ted Hibben as chief business officer of the neurology company. He was CBO at Catabasis Pharmaceuticals Inc. (NASDAQ:CATB).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD